abstract |
The present invention relates to a pharmaceutical composition according to claim 1 comprising an SGLT2 inhibitor and insulin, which are suitable for treating or preventing one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. The invention also relates to methods of preventing or treating metabolic disorders and related conditions. |